OptimizeRx (NASDAQ:OPRX) Stock Rating Lowered by TheStreet

OptimizeRx (NASDAQ:OPRX) was downgraded by stock analysts at TheStreet from a “c” rating to a “d+” rating in a note issued to investors on Wednesday, TheStreetRatingsTable reports.

Several other analysts also recently commented on the company. ValuEngine upgraded OptimizeRx from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, November 6th. B. Riley reduced their target price on OptimizeRx from $26.00 to $21.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. Finally, Zacks Investment Research downgraded OptimizeRx from a “hold” rating to a “sell” rating in a research note on Tuesday, November 5th. One investment analyst has rated the stock with a sell rating, two have issued a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $18.50.

OptimizeRx stock traded up $0.05 during trading hours on Wednesday, reaching $10.40. 41,224 shares of the company’s stock were exchanged, compared to its average volume of 91,605. The company has a quick ratio of 7.00, a current ratio of 7.00 and a debt-to-equity ratio of 0.01. The firm’s 50 day simple moving average is $12.23 and its 200 day simple moving average is $14.34. OptimizeRx has a twelve month low of $8.92 and a twelve month high of $17.24. The firm has a market capitalization of $141.31 million, a PE ratio of 208.00 and a beta of 0.42.

OptimizeRx (NASDAQ:OPRX) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.11) earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.04 by ($0.15). OptimizeRx had a negative return on equity of 3.68% and a negative net margin of 5.32%. The business had revenue of $5.00 million for the quarter, compared to analyst estimates of $7.21 million. Analysts anticipate that OptimizeRx will post -0.04 EPS for the current year.

In other news, CEO William J. Febbo bought 5,000 shares of OptimizeRx stock in a transaction dated Wednesday, November 6th. The stock was bought at an average cost of $10.38 per share, for a total transaction of $51,900.00. Company insiders own 8.40% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of the company. Wells Fargo & Company MN grew its stake in shares of OptimizeRx by 9.5% in the 2nd quarter. Wells Fargo & Company MN now owns 13,562 shares of the company’s stock valued at $219,000 after buying an additional 1,180 shares during the period. Strs Ohio acquired a new position in OptimizeRx during the 2nd quarter valued at about $51,000. Venator Capital Management Ltd. boosted its stake in OptimizeRx by 2.6% during the 2nd quarter. Venator Capital Management Ltd. now owns 214,000 shares of the company’s stock valued at $3,467,000 after purchasing an additional 5,521 shares during the last quarter. Atlantic Trust LLC acquired a new position in OptimizeRx during the 2nd quarter valued at about $126,000. Finally, Allianz Asset Management GmbH boosted its stake in OptimizeRx by 34.9% during the 2nd quarter. Allianz Asset Management GmbH now owns 50,630 shares of the company’s stock valued at $820,000 after purchasing an additional 13,111 shares during the last quarter. Institutional investors own 58.19% of the company’s stock.

About OptimizeRx

OptimizeRx Corporation provides digital health messaging services for pharmaceutical companies to communicate with healthcare providers. The company's cloud-based solutions support patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and critical clinical information; and network consists of electronic health records platforms, which provide the ambulatory patient market with access to their workflow at the point-of-care.

Read More: What is the Quick Ratio?

Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.